An analytical method for assessing stage-specific drug activity in Plasmodium vivax malaria: implications for ex vivo drug susceptibility testing.

The emergence of highly chloroquine (CQ) resistant P. vivax in Southeast Asia has created an urgent need for an improved understanding of the mechanisms of drug resistance in these parasites, the development of robust tools for defining the spread of resistance, and the discovery of new antimalarial...

Full description

Saved in:
Bibliographic Details
Main Authors: Douglas H Kerlin, Kane Boyce, Jutta Marfurt, Julie A Simpson, Enny Kenangalem, Qin Cheng, Ric N Price, Michelle L Gatton
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS Neglected Tropical Diseases
Online Access:https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0001772&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850119146065362944
author Douglas H Kerlin
Kane Boyce
Jutta Marfurt
Julie A Simpson
Enny Kenangalem
Qin Cheng
Ric N Price
Michelle L Gatton
author_facet Douglas H Kerlin
Kane Boyce
Jutta Marfurt
Julie A Simpson
Enny Kenangalem
Qin Cheng
Ric N Price
Michelle L Gatton
author_sort Douglas H Kerlin
collection DOAJ
description The emergence of highly chloroquine (CQ) resistant P. vivax in Southeast Asia has created an urgent need for an improved understanding of the mechanisms of drug resistance in these parasites, the development of robust tools for defining the spread of resistance, and the discovery of new antimalarial agents. The ex vivo Schizont Maturation Test (SMT), originally developed for the study of P. falciparum, has been modified for P. vivax. We retrospectively analysed the results from 760 parasite isolates assessed by the modified SMT to investigate the relationship between parasite growth dynamics and parasite susceptibility to antimalarial drugs. Previous observations of the stage-specific activity of CQ against P. vivax were confirmed, and shown to have profound consequences for interpretation of the assay. Using a nonlinear model we show increased duration of the assay and a higher proportion of ring stages in the initial blood sample were associated with decreased effective concentration (EC(50)) values of CQ, and identify a threshold where these associations no longer hold. Thus, starting composition of parasites in the SMT and duration of the assay can have a profound effect on the calculated EC(50) for CQ. Our findings indicate that EC(50) values from assays with a duration less than 34 hours do not truly reflect the sensitivity of the parasite to CQ, nor an assay where the proportion of ring stage parasites at the start of the assay does not exceed 66%. Application of this threshold modelling approach suggests that similar issues may occur for susceptibility testing of amodiaquine and mefloquine. The statistical methodology which has been developed also provides a novel means of detecting stage-specific drug activity for new antimalarials.
format Article
id doaj-art-1928cbcf952b4764ac587f24fff09cd3
institution OA Journals
issn 1935-2727
1935-2735
language English
publishDate 2012-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS Neglected Tropical Diseases
spelling doaj-art-1928cbcf952b4764ac587f24fff09cd32025-08-20T02:35:43ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352012-01-0168e177210.1371/journal.pntd.0001772An analytical method for assessing stage-specific drug activity in Plasmodium vivax malaria: implications for ex vivo drug susceptibility testing.Douglas H KerlinKane BoyceJutta MarfurtJulie A SimpsonEnny KenangalemQin ChengRic N PriceMichelle L GattonThe emergence of highly chloroquine (CQ) resistant P. vivax in Southeast Asia has created an urgent need for an improved understanding of the mechanisms of drug resistance in these parasites, the development of robust tools for defining the spread of resistance, and the discovery of new antimalarial agents. The ex vivo Schizont Maturation Test (SMT), originally developed for the study of P. falciparum, has been modified for P. vivax. We retrospectively analysed the results from 760 parasite isolates assessed by the modified SMT to investigate the relationship between parasite growth dynamics and parasite susceptibility to antimalarial drugs. Previous observations of the stage-specific activity of CQ against P. vivax were confirmed, and shown to have profound consequences for interpretation of the assay. Using a nonlinear model we show increased duration of the assay and a higher proportion of ring stages in the initial blood sample were associated with decreased effective concentration (EC(50)) values of CQ, and identify a threshold where these associations no longer hold. Thus, starting composition of parasites in the SMT and duration of the assay can have a profound effect on the calculated EC(50) for CQ. Our findings indicate that EC(50) values from assays with a duration less than 34 hours do not truly reflect the sensitivity of the parasite to CQ, nor an assay where the proportion of ring stage parasites at the start of the assay does not exceed 66%. Application of this threshold modelling approach suggests that similar issues may occur for susceptibility testing of amodiaquine and mefloquine. The statistical methodology which has been developed also provides a novel means of detecting stage-specific drug activity for new antimalarials.https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0001772&type=printable
spellingShingle Douglas H Kerlin
Kane Boyce
Jutta Marfurt
Julie A Simpson
Enny Kenangalem
Qin Cheng
Ric N Price
Michelle L Gatton
An analytical method for assessing stage-specific drug activity in Plasmodium vivax malaria: implications for ex vivo drug susceptibility testing.
PLoS Neglected Tropical Diseases
title An analytical method for assessing stage-specific drug activity in Plasmodium vivax malaria: implications for ex vivo drug susceptibility testing.
title_full An analytical method for assessing stage-specific drug activity in Plasmodium vivax malaria: implications for ex vivo drug susceptibility testing.
title_fullStr An analytical method for assessing stage-specific drug activity in Plasmodium vivax malaria: implications for ex vivo drug susceptibility testing.
title_full_unstemmed An analytical method for assessing stage-specific drug activity in Plasmodium vivax malaria: implications for ex vivo drug susceptibility testing.
title_short An analytical method for assessing stage-specific drug activity in Plasmodium vivax malaria: implications for ex vivo drug susceptibility testing.
title_sort analytical method for assessing stage specific drug activity in plasmodium vivax malaria implications for ex vivo drug susceptibility testing
url https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0001772&type=printable
work_keys_str_mv AT douglashkerlin ananalyticalmethodforassessingstagespecificdrugactivityinplasmodiumvivaxmalariaimplicationsforexvivodrugsusceptibilitytesting
AT kaneboyce ananalyticalmethodforassessingstagespecificdrugactivityinplasmodiumvivaxmalariaimplicationsforexvivodrugsusceptibilitytesting
AT juttamarfurt ananalyticalmethodforassessingstagespecificdrugactivityinplasmodiumvivaxmalariaimplicationsforexvivodrugsusceptibilitytesting
AT julieasimpson ananalyticalmethodforassessingstagespecificdrugactivityinplasmodiumvivaxmalariaimplicationsforexvivodrugsusceptibilitytesting
AT ennykenangalem ananalyticalmethodforassessingstagespecificdrugactivityinplasmodiumvivaxmalariaimplicationsforexvivodrugsusceptibilitytesting
AT qincheng ananalyticalmethodforassessingstagespecificdrugactivityinplasmodiumvivaxmalariaimplicationsforexvivodrugsusceptibilitytesting
AT ricnprice ananalyticalmethodforassessingstagespecificdrugactivityinplasmodiumvivaxmalariaimplicationsforexvivodrugsusceptibilitytesting
AT michellelgatton ananalyticalmethodforassessingstagespecificdrugactivityinplasmodiumvivaxmalariaimplicationsforexvivodrugsusceptibilitytesting
AT douglashkerlin analyticalmethodforassessingstagespecificdrugactivityinplasmodiumvivaxmalariaimplicationsforexvivodrugsusceptibilitytesting
AT kaneboyce analyticalmethodforassessingstagespecificdrugactivityinplasmodiumvivaxmalariaimplicationsforexvivodrugsusceptibilitytesting
AT juttamarfurt analyticalmethodforassessingstagespecificdrugactivityinplasmodiumvivaxmalariaimplicationsforexvivodrugsusceptibilitytesting
AT julieasimpson analyticalmethodforassessingstagespecificdrugactivityinplasmodiumvivaxmalariaimplicationsforexvivodrugsusceptibilitytesting
AT ennykenangalem analyticalmethodforassessingstagespecificdrugactivityinplasmodiumvivaxmalariaimplicationsforexvivodrugsusceptibilitytesting
AT qincheng analyticalmethodforassessingstagespecificdrugactivityinplasmodiumvivaxmalariaimplicationsforexvivodrugsusceptibilitytesting
AT ricnprice analyticalmethodforassessingstagespecificdrugactivityinplasmodiumvivaxmalariaimplicationsforexvivodrugsusceptibilitytesting
AT michellelgatton analyticalmethodforassessingstagespecificdrugactivityinplasmodiumvivaxmalariaimplicationsforexvivodrugsusceptibilitytesting